First Patient in Japan Treated with Impella 5.5 with SmartAssist
The versatility and innovation of Abiomed’s (NASDAQ: ABMD) Impella 5.5 with SmartAssist, a minimally-invasive forward flow heart pump, is leading to continued adoption of the game-changing technology by surgeons around the world. Today, Abiomed announces the first patient in Japan has been treated successfully with Impella 5.5 with SmartAssist. Additionally, the number of patients treated globally has surpassed 5,000.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406005156/en/
Surgeons at Osaka Police Hospital view a fluoroscopy image showing Impella 5.5 with SmartAssist pumping in the patient’s heart during the first procedure in Japan. (Photo: Business Wire)
The first Impella 5.5 with SmartAssist procedure in Japan took place at Osaka Police Hospital when an 82-year-old man was treated for cardiogenic shock. “Our facility is proud to be the first in Japan to treat patients using Impella 5.5 with SmartAssist,” said Yoshiki Sawa, MD, PhD, director at Osaka Police Hospital. “We are excited to utilize this innovative technology and look forward to providing a minimally invasive surgical option for our acute heart failure patients.”
The milestone 5,000th procedure was performed by Tamer Attia, MD, at Emory University Hospital in Atlanta on a 41-year-old woman with cardiomyopathy. “Impella 5.5 with SmartAssist has completely changed how we are able to support our cardiogenic shock and cardiomyopathy patients,” said Mani Daneshmand, MD, chief of the section of thoracic transplant and mechanical circulatory support surgery at Emory University Hospital. “Given the safety and efficacy of Impella 5.5 with SmartAssist, Dr. Attia and his team are able to treat patients who otherwise would not have had other options for heart recovery.”
Impella 5.5 with SmartAssist is:
- Minimally invasive, eliminating the need for a sternotomy or coring of the left ventricle;
- Designed for heart surgeons, implanted via the axillary artery or the anterior aorta;
- Forward flow, to provide the patient with coronary flow and renal perfusion;
- Fully unloading, to reduce the heart’s oxygen demand and work; and
- Equipped with SmartAssist, designed to provide weaning algorithms to optimize survival and native heart recovery.
Additionally, more than 90% of patients are securely monitored in the cloud via Impella Connect, giving providers access to Impella status data 24/7.
Impella 5.5 with SmartAssist, which was granted the highest level of approval for safety and efficacy by the U.S. Food and Drug Administration (FDA) in 2019, is now being used in more than 350 centers across the U.S. for indications that include AMI cardiogenic shock, cardiomyopathy and post-cardiotomy cardiogenic shock. Historically, the cardiogenic shock survival rate has been approximately 50%. Published in Innovations, a study of 200 patients treated with Impella 5.5 with SmartAssist at 42 medical centers in the United States demonstrates a 74% survival to explant, with 58% of those patients achieving native heart recovery.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® devices are US FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are US FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005156/en/
Contact information
United States Media:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com
Japan Media:
Itsuki Shinohara
Manager, Public Relations
+81-3-4540-5600
ishinohara@abiomed.com
Investor:
Todd Trapp
Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The AgreenaCarbon Project Becomes the First Large-Scale Soil Carbon Project to Achieve Verra Verification, Now Issuing 2.3 Million Verified Carbon Credits15.9.2025 11:30:00 EEST | Press release
Agreena, the company powering the global transition to regenerative agriculture, has achieved verification of its AgreenaCarbon Project under Verra’s Verified Carbon Standard (VCS) Program’s VM0042 Improved Agricultural Land Management v2.0 methodology – the first large-scale arable agriculture project to do so. By passing this milestone, Agreena is now issuing 2.3 million Verra-verified carbon credits that are not only readily available, but deliver immediate, measurable climate impact. This follows the project’s successful validation in January 2025. While validation confirms that the project design and methodology meet the requirements of Verra’s VCS Program, verification is the critical next step - confirming, through independent assessment, that the project has delivered measurable climate outcomes as intended. Verra’s VCS Program is the world’s most widely recognised greenhouse gas crediting standard and is approved by the Integrity Council for the Voluntary Carbon Market. Unlike
Libertex Voted “Best CFD Broker - Europe” at Global Forex Awards15.9.2025 11:23:00 EEST | Press release
Multi-awarded online broker Libertex adds another accolade in its trophy case as it has been named Europe's Best CFD Broker by Global Forex Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915045703/en/ (Photo: Libertex) This title not only highlights the broker’s role as a trusted leader, but it also reflects Libertex’s commitment to delivering excellence on all levels. Applying to an exhaustive set of the company’s services, from client support to trading technology, education, and asset coverage, the accolade bolsters the broker’s position in the global CFD trading arena while shining a spotlight on its continuous efforts to stay relevant. Speaking about the recent win, Libertex Group CMO Marios Chailis said: “We are truly honoured to be recognised as ‘Best CFD Broker - Europe’ at the Global Forex Awards. This award reflects not only the efforts of our dedicated team but also the confidence our clients place in u
Hanshow and Delfi Partner to Expand Digital Solutions in Europe15.9.2025 11:04:00 EEST | Press release
Hanshow, a global leader in Electronic Shelf Labels (ESLs) and digital retail solutions, and Delfi Technologies, a Danish retail technology pioneer with decades of expertise in ESL platforms, today announced a new partnership, marking the start of closer cooperation to expand ESL offerings for retailers across Europe and accelerate the next phase of in-store digital transformation. Through this partnership, Delfi Technologies’ Breece System platform will be strengthened with Hanshow’s world-class ESL portfolio, proven in thousands of deployments worldwide. This partnership combines Delfi’s experience with ESL deployments in Europe and Hanshow’s global innovation leadership. Together, Hanshow will bring more flexibility, more options, and more value to retailers, helping them accelerate their digital transformation with lower costs and greater impact. The partnership also reinforces both companies’ commitment to sustainability. By replacing paper-based processes with digital price manag
SES Partners with Cailabs to Test Next-Generation Laser Communication Technology15.9.2025 11:00:00 EEST | Press release
SES, a leading space solutions company, announced today it will test new optical ground stations built by France-based Cailabs to send data from space using laser beams instead of radio waves. By using optical communication, SES expects to be able to boost data transmission speeds, provide more secure links, and help alleviate congestion in increasingly crowded radio frequency bands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915922379/en/ SES Partners with Cailabs to Test Next-Generation Laser Communication Technology. Credit: Cailabs The partnership marks a major step forward for optical communications, which use light beams to transmit data at speeds of up to 10 gigabits per second—about 100 times faster than typical home internet. Unlike traditional radio signals, laser beams are nearly impossible to intercept or jam, making them ideal for secure government and business communications. The biggest challenge with o
Prometheus Slashes Cost of Carbon Capture by More Than 80%, Unlocking Affordable E-Fuels as a New Source of 24/7 Carbon Neutral Power15.9.2025 11:00:00 EEST | Press release
Prometheus Fuels (Prometheus), the company producing low-cost carbon neutral fuels from direct air capture and renewable electricity, today announced it has achieved the lowest-cost carbon capture in the world, reducing the cost of Direct Air Capture (DAC) by more than 80 percent compared to industry averages. At under $50 per ton, Prometheus’ DAC cost breakthrough unlocks carbon neutral fuels at fossil fuel prices, without relying on subsidies, biogenic carbon, or point-source emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915079297/en/ Prometheus builds a 200-ton-per-year Direct Air Capture system at its California HQ, adding capacity to its currently operating 16-TPY system, the world’s lowest-cost DAC technology at less than $50 per ton CO₂. The achievement is demonstrated in Prometheus’ new 200-ton-per-year DAC system, currently under construction and scheduled for completion this year. The system captures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom